K
Kamada is a growing commercial-stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions. The company is a leader in the specialty plasma-derived field focused on diseases with limited treatment alternatives, with 6 FDA-approved products selling in over 30 countries. The company is advancing an innovative development pipeline targeting areas of significant unmet medical need.
Investor insights
Funding rounds participated in
$60M sweet spot round size
Investor type
Public Company
Basic info
Industry
Pharmaceutical Manufacturing
Sectors
Pharmaceutical Manufacturing
Date founded
1990
Funding rounds raised
Total raised
$60M
from 1 investors over 1 rounds
K
KAMADA raised $60M on June 24, 2023
Investors: First Israel Mezzanine Investors